Fredun Pharmaceuticals Board Meeting Scheduled on May 25, 2026 to Consider Q4FY26 Results, Dividend, and Bonus Shares

Fredun Pharmaceuticals Limited has notified the BSE of an upcoming board meeting scheduled for Monday, May 25, 2026, in accordance with Regulation 29 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated May 15, 2026, was submitted by Director Fredun Nariman Medhora (DIN: 01745348).

Key Agenda Items

The board meeting has been convened to deliberate on several significant matters pertaining to the financial year ended March 31, 2026. The following items are on the agenda:

Agenda Item: Details Financial Results: Audited Financial Results & Statements (Standalone & Consolidated) for Q4 and FY ended March 31, 2026 Final Dividend: Consider and recommend final dividend on paid-up equity shares for FY ended March 31, 2026 Bonus Equity Shares: Consider and recommend Bonus Equity Shares, subject to approval of Members of the Company

Trading Window Closure

In compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of Fredun Pharmaceuticals shall remain closed until the expiry of 48 hours after the declaration of the financial results. Market participants and insiders are advised to take note of this restriction accordingly.

Regulatory Compliance

The board meeting intimation has been filed in accordance with applicable SEBI listing regulations. The notice was digitally signed by Director Fredun Nariman Medhora on May 15, 2026, at 11:37:00 IST, confirming the company's adherence to disclosure requirements under the applicable regulatory framework.

Fredun Pharmaceuticals Limited has announced the opening of a new manufacturing facility in Palghar, Maharashtra, representing a significant milestone in the company's expansion strategy. The facility marks the addition of the company's fifth manufacturing unit and demonstrates its commitment to strengthening its manufacturing footprint across the healthcare industry.

Facility Specifications and Timeline

The new manufacturing facility spans 40,000 sq. ft. and is expected to become operational by October 2026. This expansion represents a strategic move to enhance the company's production capabilities and meet growing domestic and international demand across its diversified product portfolio.

Parameter: Details Facility Size: 40,000 sq. ft. Location: Palghar, Maharashtra Expected Operational Date: October 2026 Facility Number: Fifth manufacturing facility Planned Additional Expansion: 50,000 sq. ft.

Strategic Manufacturing Expansion

The facility will support key product categories including veterinary products, supportive nutraceuticals, and pharmaceutical formulations. The company has outlined several expected operational benefits from this expansion, including enhanced efficiency, improved production scalability, and the ability to meet growing market demand.

Additionally, Fredun Pharmaceuticals has planned a 50,000 sq. ft. expansion to be undertaken under strategic growth initiatives, further demonstrating its commitment to scaling operations. The integration with existing facilities is expected to strengthen the company's presence across pharmaceutical and nutraceutical sectors.

Management Commentary

Commenting on the development, Mr. Fredun Medhora, Managing Director, stated: "As our business continues to expand, we are gradually strengthening our manufacturing footprint to stay aligned with our requirements. With opportunities opening up across our key segments, our focus remains on building a stronger and more scalable foundation."

Company Profile and Financial Performance

Fredun Pharmaceuticals Limited operates as a healthcare and pharmaceuticals company offering a diverse range of products. The company's portfolio includes antihypertensives, antidiabetic medications, antiretroviral drugs (ARVs), and narcotics. It is also engaged in manufacturing dietary and herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products, along with animal healthcare products.

The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America. With such a diverse product range, the company positions itself as a holistic healthcare provider.

Financial Metric: FY25 Performance Total Revenues: ₹ 456 Cr EBITDA: ₹ 55 Cr PAT: ₹ 21 Cr

The opening of the fifth manufacturing facility aligns with the company's objective to maintain high standards of quality, compliance, and innovation while strengthening its position as a leading manufacturing partner in the healthcare industry.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.